Luca Issi
Stock Analyst at RBC Capital
(3.76)
# 723
Out of 5,150 analysts
220
Total ratings
49.64%
Success rate
8.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $13.19 | +13.72% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $236.54 | +16.26% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $725.20 | +22.72% | 4 | Feb 27, 2026 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $22 → $26 | $25.80 | +0.78% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $25 → $30 | $52.40 | -42.75% | 19 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $500 → $465 | $324.94 | +43.10% | 29 | Jan 20, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $75.36 | +26.06% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $64.82 | +23.42% | 11 | Dec 11, 2025 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $9 → $27 | $13.48 | +100.30% | 6 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $7 → $10 | $8.13 | +23.00% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $28.28 | -0.99% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $10.71 | -25.30% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $56.80 | -11.97% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $8.56 | +121.96% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $14.73 | +103.67% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $45 | $10.26 | +338.60% | 7 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.32 | +331.03% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $20.16 | -10.71% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $6.74 | +196.74% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.38 | +425.07% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $10.42 | +63.15% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.82 | +90.62% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $8.58 | +307.93% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $60.51 | +15.68% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $46.82 | +21.74% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.93 | +107.79% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $21.67 | +255.33% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.70 | +725.96% | 5 | Aug 7, 2024 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $13.19
Upside: +13.72%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $236.54
Upside: +16.26%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $725.20
Upside: +22.72%
Beam Therapeutics
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $25.80
Upside: +0.78%
Moderna
Feb 17, 2026
Maintains: Sector Perform
Price Target: $25 → $30
Current: $52.40
Upside: -42.75%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Outperform
Price Target: $500 → $465
Current: $324.94
Upside: +43.10%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $75.36
Upside: +26.06%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $64.82
Upside: +23.42%
Wave Life Sciences
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $13.48
Upside: +100.30%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $8.13
Upside: +23.00%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $28.28
Upside: -0.99%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $10.71
Upside: -25.30%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $56.80
Upside: -11.97%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $8.56
Upside: +121.96%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $14.73
Upside: +103.67%
Nov 4, 2025
Maintains: Outperform
Price Target: $65 → $45
Current: $10.26
Upside: +338.60%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.32
Upside: +331.03%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $20.16
Upside: -10.71%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $6.74
Upside: +196.74%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.38
Upside: +425.07%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $10.42
Upside: +63.15%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $6.82
Upside: +90.62%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $8.58
Upside: +307.93%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $60.51
Upside: +15.68%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $46.82
Upside: +21.74%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.93
Upside: +107.79%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $21.67
Upside: +255.33%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.70
Upside: +725.96%